Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.65 |
| ▸ | GSR | P00390 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 2/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.58 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.58 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211297 | 1.00 | HDAC1 (0.65) | HDAC1HDAC8HDAC6GSRMAPT | |
| SCHEMBL12852987 | 1.00 | HDAC1 (0.65) | HDAC1HDAC8HDAC6GSRMAPT | |
| SCHEMBL29393232 | 1.00 | HDAC1 (0.65) | HDAC1HDAC8HDAC6GSRMAPT | |
| Hydrochloric Acid SCHEMBL11754749 | 0.98 | HDAC1 (0.62) | HDAC1HDAC8HDAC6GSRMAPT | |
| SCHEMBL11462614 | 0.98 | HDAC1 (0.62) | HDAC1HDAC8HDAC6GSRMAPT | |
| Juarezic Acid SCHEMBL7524344 | 0.87 | HDAC1 (0.55) | HDAC1HDAC8HDAC6GSRMAPT | |
| SCHEMBL1399154 | 0.86 | HDAC1 (0.54) | HDAC1HDAC8HDAC6GSRMAPT | |
| SCHEMBL1233338 | 0.86 | HDAC1 (0.54) | HDAC1HDAC8HDAC6GSRMAPT | |
| SCHEMBL2744242 | 0.85 | GSR (0.79) | HDAC1HDAC8HDAC6GSRMAPT | |
| SCHEMBL22596712 | 0.85 | HDAC1 (0.67) | HDAC1HDAC8HDAC6GSRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 646 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497636-B2 | Recombinant Saccharomyces cerevisiae cells for cannabinoid production | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2025-12-16 | — | — | US | claimed |
| CN-115594675-B | Beta-carbalin-cinnamic acid skeleton derivative and preparation method and application thereof | 西安医学院 | 2024-01-30 | — | — | CN | claimed |
| EP-4289425-A2 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | Tseng, Yufeng, Jane (US) | 2023-12-13 | — | — | EP | claimed |
| CN-116949024-A | Phenylalanine ammonia lyase mutant and application thereof in synthesis of (S) -2-chloro-phenylalanine | 江南大学 | 2023-10-27 | — | — | CN | claimed |
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | YODA THERAPEUTICS INC. (TW) | 2023-01-19 | — | — | US | claimed |
| CN-115594675-A | Beta-carbalin-cinnamic acid skeleton derivative and preparation method and application thereof | 西安医学院（CN） | 2023-01-13 | — | — | CN | claimed |
| EP-4108240-A2 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | Yoda Pharmaceuticals Inc. (KY) | 2022-12-28 | — | — | EP | claimed |
| US-11370775-B2 | Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors | Tseng, Yufeng Jane (US) | 2022-06-28 | — | — | US | claimed |
| US-20200361894-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | NATIONAL YANG MING CHIAO TUNG UNIVERSITY (TW) | 2020-11-19 | — | — | US | claimed |
| CN-109265458-B | Matrine-based antitumor drug compound | 中国医学科学院药用植物研究所 | 2020-09-15 | — | — | CN | claimed |
| EP-1526584-A2 | Photosensitive semiconductor nanocrystals, photosensitive composition comprising semiconductor nanocrystals and method for forming semiconductor nanocrystal pattern using the same | Samsung Electronics Co., Ltd (KR) | 2005-04-27 | — | — | EP | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| WO-2003031492-A1 | THERMALLY REWORKABLE EPOXY RESINS AND COMPOSITIONS BASED THEREO N | HENKEL CORPORATION (US) | 2003-04-17 | — | — | WO | claimed |
| US-6503413-B2 | Polyalkylene polysiloxane, buffering agent, aqueous carrier | THE PROCTER & GAMBLE COMPANY | 2003-01-07 | — | — | US | claimed |
| US-20020011584-A1 | Stable, aqueous compositions for treating surfaces, especially fabrics | THE PROCTOR & GAMBLE COMPANY | 2002-01-31 | — | — | US | claimed |
| US-20020010154-A1 | Compositions comprising cyclodextrin | THE PROCTER & GAMBLE COMPANY | 2002-01-24 | — | — | US | claimed |
| EP-0711268-B1 | METHOD FOR PREPARING ALKOXYLATION PRODUCTS IN THE PRESENCE OF ADDITIVE-MODIFIED MIXED HYDROXIDES | BASF AG (DE) | 1998-10-28 | — | — | EP | claimed |
| EP-0327021-B1 | COATING COMPOSITIONS FOR PREVENTING ADHESION OF AQUATIC ORGANISMS | KANSAI PAINT CO. LTD. (JP) | 1993-06-09 | — | — | EP | claimed |
| US-4356247-A | LITHOGRAPHY; PRINTING PLATES; PHOTORESISTS; HIGH-SPEED SENSITIZERS; SOTRAGE STABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1982-10-26 | — | — | US | claimed |
| US-4284832-A | Conversion of CS (tear gas) to o-chlorostyrene and ammonium sulfate | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1981-08-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | HDAC1 509/4885HDAC8 1943/4885HDAC6 972/4885 |
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | NLRP3, NOD1, NLRP1 | HDAC1 68/4885HDAC8 157/4885HDAC6 96/4885 |
| US-11370775-B2 | Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors | DAO, DDO, IL4I1 | HDAC1 814/4885HDAC8 1387/4885HDAC6 734/4885 |
| US-20020010154-A1 | Compositions comprising cyclodextrin | FFAR4, FRG1, FGB | HDAC1 2480/4885HDAC8 2105/4885HDAC6 2688/4885 |
| US-20200361894-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | DAO, DDO, DDC | HDAC1 702/4885HDAC8 844/4885HDAC6 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.